TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02768363

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: aglatimagene besadenovec
Description: Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: valacyclovir
Description: Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
Study: NCT00981370

Intervention type: DRUG
Group type: OTHER
Intervention: deferasirox
Description: Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
Study: NCT03846804

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Karius Test
Description: Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
Study: NCT00371280

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orbital implant
Description: Implantation of pegged versus unpegged hydroxyapatite orbital implants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orbital implant
Description: Implantation of pegged versus unpegged hydroxyapatite orbital implants
Study: NCT01721993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Study: NCT02211079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911
Description: JNJ-54861911, 50 mg (2\*25 mg tablets) orally once daily from Day 2 to Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
Study: NCT00001880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Description: Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
Study: NCT01441180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS7977
Description: drug intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS7977
Description: drug intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS7977
Description: drug intervention
Study: NCT00946751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
Study: NCT01596725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1)
Description: Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1)
Description: Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo; intramuscular, deltoid, Day 0 and Day 21
Study: NCT03985917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singing Group Intervention Program
Description: Each session will start with (1) relaxation, vocal warm-up and breething exercises; (2) vocal technique training; (3) memorization and interpretation of music and lyrics; (4) session breaks of 20 minutes for socialization; (5) preparation of a final choir show; (6) vocal tuning tests.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Social and Leisure Activities
Description: Day care centers provide social and leisure activities opportunities for older adults. The control group is free to enroll in these activities.
Study: NCT01565928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: 4 x 40 mg capsules, orally, once per day
Study: NCT00339469

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: LIFE
Description: We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
Study: NCT01771887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education program
Description: education program in 6 hours and monitoring phone every 15 days
Study: NCT03682328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertebroplasty
Description: Cement augmentation of the vertebral body

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kyphoplaty
Description: Cement augmentation of the vertebral body
Study: NCT04554823

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Exercise
Description: Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
Study: NCT02684565

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BCAA High Protein supplement
Description: Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BCAA Low Protein supplement
Description: Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
Study: NCT01441180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: drug intervention
Study: NCT04943380

Intervention type: DIAGNOSTIC_TEST
Intervention: Cxbladder
Description: The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
Study: NCT00130637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Study: NCT03526081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chamomile Tea
Description: Chamomile Tea in 300mL hot water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parsley based drink
Description: 3.2 g dried parsley in 300mL hot water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parsley Yogurt
Description: 3.2 g dried parsley in 100g plain yogurt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apigenin
Description: Apigenin capsule mixed with 300mL hot water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parsley-based drink (II)
Description: 3.2 g dried parsley in 300mL hot water
Study: NCT00994149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: 10mg/kg/d divide every 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ora-plus
Description: placebo, give every 8 hours.
Study: NCT04227990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Study: NCT01441180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: drug intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: drug intervention
Study: NCT01686061

Intervention type: OTHER
Intervention: No intervention- only one time survey
Study: NCT00772616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: closed-loop administration using bispectral index as the single input for the controller.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: dosage according to usual criteria
Study: NCT01049100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphadenectomy
Description: paraaortal and pelvic lymphadenectomy laparoscopic or open

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard Staging
Description: clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--\> CT controlled biopsy
Study: NCT02789995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
Study: NCT00142298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine (LdT)
Description: Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
Study: NCT02420340

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HOPES Program (Helping Older People Experience Success)
Description: Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
Study: NCT00797771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adi Insulin pump
Description: insulin delivery will be defined by the physician
Study: NCT00242216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir-boosted atazanavir
Description: 100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir-boosted fosamprenavir
Description: 100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
Study: NCT03145974

Intervention type: DEVICE
Intervention: mechanical ventilation
Description: ventilatory support
Study: NCT01675791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 0.5 DU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 1 DU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 2 DU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 4 DU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 7 DU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 12 DU

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALK tree AIT Placebo
Study: NCT04049643

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Audiologist-based fitting
Description: Hearing aids will be fitted by audiologists using established procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Service-only Fitting
Description: This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. In this intervention group, audiological services plus hearing aids that provide minimum amplification will be provided. Specifically, patient participants in this group will receive audiological services (e.g., counselling and education), except that the hearing aids will be set to provide no amplification other than what is needed to overcome any sounds that are dampened by the earpieces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device-only fitting
Description: This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. The patient participants in this intervention group will have minimum services regarding the pre-fitting, selection, and orientation of the hearing aids. The participants will have a hearing evaluation, including pure-tone audiometry. The audiologist will select the amplification characteristics and non-custom ear piece based on the audiogram. The audiologist will then briefly orient the participant on how to use the hearing aids and counsel on how to optimize their performance.
Study: NCT02564549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS-guided biopsy
Description: Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mpMRI with targeted biopsy
Description: Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
Study: NCT00660699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study: NCT00926055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetrol (Ezetimibe)
Description: Ezetrol - 10 mg once daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vytorin (Ezetimibe + Simvastatin)
Description: Vytorin - 10/20 mg once daily for 3 months
Study: NCT02932475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg twice a day

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Delivered to match active drug
Study: NCT04586894

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy

Intervention type: DEVICE
Intervention: Smart cloth
Description: A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.

Intervention type: OTHER
Intervention: Biobanking
Description: Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
Study: NCT00112099

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery: Splenectomy
Description: Procedure/Surgery: Surgery: Splenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery: Spleen-preservation
Description: Procedure/Surgery: Surgery: Spleen-preservation
Study: NCT01399801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler flow measurement
Description: use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard implantation of the LV lead
Description: Standard implantation of the LV lead with measurements of flow
Study: NCT01031524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfCS102
Description: Antigen of the sporozoite protein

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Montanide ISA 720
Description: adjuvant alone
Study: NCT02923596

Intervention type: PROCEDURE
Intervention: History of prior Surgery
Description: History of prior Surgery will be reviewed

Intervention type: PROCEDURE
Intervention: History of prior Surgery
Description: History of prior Surgery will be reviewed

Intervention type: PROCEDURE
Intervention: History of prior Surgery
Description: History of prior Surgery will be reviewed

Intervention type: RADIATION
Intervention: History of Radiation Therapy
Description: History of prior radiation therapy will be reviewed

Intervention type: RADIATION
Intervention: History of Radiation Therapy
Description: History of prior radiation therapy will be reviewed

Intervention type: RADIATION
Intervention: History of Radiation Therapy
Description: History of prior radiation therapy will be reviewed
Study: NCT03105583

Intervention type: DRUG
Intervention: Medication use during pregnancy

Intervention type: DIETARY_SUPPLEMENT
Intervention: Supplement use during pregnancy

Intervention type: OTHER
Intervention: Vitamin status of a pregnant woman
Description: Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
Study: NCT00876421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo / 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: 4mg / 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: low dose / 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: medium dose / 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: higher dose / 12 weeks